Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

Summary

This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis. Participants will be stratified by prior therapeutic treatment and Mayo score at Baseline, and will be randomized 1:1:1 to receive E6007 30 milligrams (mg), E6007 60 mg or placebo.

Timeline

Start

2016-11-28

Primary completion

2019-04-17

Completion

2019-08-16

Drugs

Indications